STAURINZ 25MG SOFT GELATIN CAPSULE is used to manage acute myeloid leukaemia (AML) in adults who have a defect in a gene called FLT3. It is also used in adults to manage aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated haematological neoplasm (SM-AHN), or mast cell leukaemia (MCL). These are disorders in which the body produces too many mast cells (a type of white blood cell).
STAURINZ 25MG SOFT GELATIN CAPSULE contains Midostaurin which belongs to the group of medicines called Protein kinase inhibitors which blocks the action of some enzymes (kinases) in the cancerous cells and stops their division and growth.
Your doctor will perform regular blood tests during treatment with STAURINZ 25MG SOFT GELATIN CAPSULE in order to monitor the amount of blood cells (white blood cells, red blood cells and platelets) and electrolytes (e.g. calcium, potassium, magnesium) in your body. Your heart and lung function will also be checked regularly.
Before taking STAURINZ 25MG SOFT GELATIN CAPSULE, inform your doctor if you have any infections, heart or lung problems. It should be used with caution in patients with liver problems due to alcohol to manage the risk of liver damage.
STAURINZ 25MG SOFT GELATIN CAPSULE is not recommended for use in pregnant and breastfeeding women. STAURINZ 25MG SOFT GELATIN CAPSULE is not recommended for use in children and adolescents less than 18 years of age.
The most common side effects of taking STAURINZ 25MG SOFT GELATIN CAPSULE include red or purple, flat, pinhead spots under the skin, problems falling asleep, headache, dizziness, shortness of breath, respiratory infections, mouth sores, nausea, vomiting, upper abdominal pain, piles, excessive sweating, thirst, back pain, joint pain, neck pain, muscle pain, high urine output, dark urine, dry flushed skin, abnormal heart rhythm, swelling of the eyelid and weight gain. Consult your doctor if any symptoms worsens.
No content available
